Peak Bio, Inc. financial data

Location
Pleasanton, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 12 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 7.6% % -41%
Debt-to-equity -109% % 11%
Return On Equity 16% % -87%
Return On Assets -179% % 68%
Operating Margin -8291% % -168%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23,124,888 shares 5.6%
Common Stock, Shares, Outstanding 23,124,888 shares 2.2%
Common Stock, Value, Issued $2,312 USD 2.2%
Weighted Average Number of Shares Outstanding, Basic 23,124,888 shares 6.9%
Weighted Average Number of Shares Outstanding, Diluted 28,440,646 shares -21%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $75,192 USD -86%
Research and Development Expense $281,265 USD -87%
General and Administrative Expense $6,028,006 USD -50%
Operating Income (Loss) $6,234,079 USD 64%
Nonoperating Income (Expense) $2,910,004 USD 31%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $3,324,075 USD 83%
Earnings Per Share, Basic 0 USD/shares 87%
Earnings Per Share, Diluted 0 USD/shares 87%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $862,144 USD 813%
Assets, Current $1,537,308 USD 22%
Property, Plant and Equipment, Net $27,496 USD -85%
Other Assets, Noncurrent $11,136 USD 123%
Assets $1,635,940 USD 8.4%
Accounts Payable, Current $5,356,730 USD -5.8%
Accrued Liabilities, Current $4,495,752 USD 44%
Liabilities, Current $22,397,935 USD 20%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $22,544,185 USD 18%
Accumulated Other Comprehensive Income (Loss), Net of Tax $110,455 USD -15%
Retained Earnings (Accumulated Deficit) $40,970,115 USD -8.8%
Stockholders' Equity Attributable to Parent $20,908,245 USD -19%
Liabilities and Equity $1,635,940 USD 8.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,417,672 USD 1.6%
Net Cash Provided by (Used in) Financing Activities $1,108,163 USD -3.2%
Common Stock, Shares Authorized 60,000,000 shares 0%
Common Stock, Shares, Issued 23,124,888 shares 2.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $922,144 USD 497%
Interest Paid, Excluding Capitalized Interest, Operating Activities $50,947 USD
Depreciation $31,845 USD -23%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $3,297,005 USD 83%
Operating Lease, Liability, Current $0 USD -100%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $19,949,103 USD 0.01%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $69,312 USD -114%
Interest Expense $2,440,269 USD 121%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%